JP6483117B2 - Ａｐｌｎｒモジュレーター及びその使用 - Google Patents

Ａｐｌｎｒモジュレーター及びその使用 Download PDF

Info

Publication number
JP6483117B2
JP6483117B2 JP2016532590A JP2016532590A JP6483117B2 JP 6483117 B2 JP6483117 B2 JP 6483117B2 JP 2016532590 A JP2016532590 A JP 2016532590A JP 2016532590 A JP2016532590 A JP 2016532590A JP 6483117 B2 JP6483117 B2 JP 6483117B2
Authority
JP
Japan
Prior art keywords
antibody
aplnr
apelin
antigen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016532590A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500018A5 (enExample
JP2017500018A (ja
Inventor
パナイオティス・ステーヴィス
ジェスパー・グロマーダ
アンドリュー・ジェイ・マーフィー
ヤナトン・レイ
ジー・エイチ・キム
アイヴァン・ビー・ロボヴ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52021453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6483117(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2017500018A publication Critical patent/JP2017500018A/ja
Publication of JP2017500018A5 publication Critical patent/JP2017500018A5/ja
Application granted granted Critical
Publication of JP6483117B2 publication Critical patent/JP6483117B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016532590A 2013-11-20 2014-11-20 Ａｐｌｎｒモジュレーター及びその使用 Active JP6483117B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906568P 2013-11-20 2013-11-20
US61/906,568 2013-11-20
PCT/US2014/066687 WO2015077491A1 (en) 2013-11-20 2014-11-20 Aplnr modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019022363A Division JP6738449B2 (ja) 2013-11-20 2019-02-12 Ａｐｌｎｒモジュレーター及びその使用

Publications (3)

Publication Number Publication Date
JP2017500018A JP2017500018A (ja) 2017-01-05
JP2017500018A5 JP2017500018A5 (enExample) 2017-12-28
JP6483117B2 true JP6483117B2 (ja) 2019-03-13

Family

ID=52021453

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016532590A Active JP6483117B2 (ja) 2013-11-20 2014-11-20 Ａｐｌｎｒモジュレーター及びその使用
JP2019022363A Active JP6738449B2 (ja) 2013-11-20 2019-02-12 Ａｐｌｎｒモジュレーター及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019022363A Active JP6738449B2 (ja) 2013-11-20 2019-02-12 Ａｐｌｎｒモジュレーター及びその使用

Country Status (15)

Country Link
US (7) US10155811B2 (enExample)
EP (1) EP3071600B1 (enExample)
JP (2) JP6483117B2 (enExample)
KR (1) KR20160086942A (enExample)
CN (1) CN105916881A (enExample)
AU (1) AU2014352962B2 (enExample)
BR (1) BR112016011401A2 (enExample)
CA (1) CA2931299C (enExample)
CL (1) CL2016001212A1 (enExample)
EA (1) EA201691027A1 (enExample)
IL (1) IL245733A0 (enExample)
MA (1) MA39061A1 (enExample)
MX (1) MX377716B (enExample)
PH (1) PH12016500943A1 (enExample)
WO (1) WO2015077491A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
JP5997151B2 (ja) 2011-06-30 2016-09-28 中外製薬株式会社 ヘテロ二量化ポリペプチド
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CA3233142A1 (en) 2011-11-30 2013-06-06 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
WO2014152955A1 (en) 2013-03-14 2014-09-25 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
WO2015077491A1 (en) 2013-11-20 2015-05-28 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
US11104730B2 (en) 2013-11-20 2021-08-31 Regeneren Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
EP3355920A4 (en) * 2015-09-29 2019-05-15 Celgene Corporation PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
WO2018053405A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
AU2018266324B2 (en) * 2017-05-06 2024-02-01 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
CN119613548A (zh) * 2018-06-13 2025-03-14 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
IL317002A (en) 2018-08-10 2025-01-01 Chugai Pharmaceutical Co Ltd Anti-CD137 antigen binding molecule and use thereof
CN114096562B (zh) 2019-05-15 2025-02-21 中外制药株式会社 抗原结合分子、药物组合物和方法
US20220220214A1 (en) * 2019-06-19 2022-07-14 Ab Initio Biotherapeutics, Inc. Apj modulators and uses thereof
GB202015755D0 (en) * 2020-10-05 2020-11-18 Rogers Arpi Coronavirus therapy
CN117065020A (zh) * 2023-02-17 2023-11-17 山东大学 抑制aplnr表达或降低aplnr活性的物质在制备治疗瘢痕药物中的应用
WO2025194171A1 (en) * 2024-03-15 2025-09-18 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of g protein-coupled receptors
EP4660299A1 (en) 2024-06-06 2025-12-10 Philipps-Universität Marburg Production of blood and immune cell progenitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
AU1685499A (en) 1997-12-24 1999-07-19 Takeda Chemical Industries Ltd. Polypeptide, their production and use
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
AU2001296023A1 (en) 2000-10-30 2002-05-15 Takeda Chemical Industries Ltd. Process for producing peptide
US7119185B2 (en) 2000-12-21 2006-10-10 Trustees Of The University Of Pennsylvania Hormonally up-regulated, neu-tumor-associated kinase
DE10138569A1 (de) 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
EP1613348B1 (en) 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Methods for modulating angiogenesis with apelin compositions
BRPI0507174A (pt) 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
US20060045880A1 (en) 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions
WO2006076736A2 (en) * 2005-01-14 2006-07-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US7713521B2 (en) * 2005-08-12 2010-05-11 Schering Corporation MCP1 fusions
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US20090233854A1 (en) 2005-12-20 2009-09-17 Takeda Pharmaceutical Company Limited Novel application of apelin
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses
KR100897938B1 (ko) 2007-05-30 2009-05-18 주식회사 제넥신 면역글로불린 융합 단백질
CN102203117A (zh) 2008-11-04 2011-09-28 安科治疗公司 Apj受体化合物
US20110305692A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Antigen-binding contructs
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
DK3202898T3 (en) 2009-11-02 2019-01-14 Univ Washington THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
SI3045183T1 (sl) 2011-03-11 2018-11-30 Genzyme Corporation Pegiliran Apelin in njegove uporabe
CN103458910A (zh) 2011-03-31 2013-12-18 株式会社资生堂 潮热抑制剂
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
WO2013079487A1 (en) 2011-11-28 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
CN102516393B (zh) 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
NZ631565A (en) 2012-03-14 2016-07-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
JP6426107B2 (ja) 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
WO2014152955A1 (en) 2013-03-14 2014-09-25 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
WO2015077491A1 (en) 2013-11-20 2015-05-28 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof

Also Published As

Publication number Publication date
US20190177410A1 (en) 2019-06-13
US20210403551A1 (en) 2021-12-30
CA2931299A1 (en) 2015-05-28
US20190048074A1 (en) 2019-02-14
PH12016500943A1 (en) 2016-06-27
US20170058028A1 (en) 2017-03-02
KR20160086942A (ko) 2016-07-20
AU2014352962B2 (en) 2019-11-07
EP3071600B1 (en) 2020-06-17
BR112016011401A2 (pt) 2017-09-26
IL245733A0 (en) 2016-07-31
WO2015077491A1 (en) 2015-05-28
JP2019094343A (ja) 2019-06-20
EP3071600A1 (en) 2016-09-28
MX2016006709A (es) 2016-09-08
JP2017500018A (ja) 2017-01-05
AU2014352962A1 (en) 2016-06-23
US20150252107A1 (en) 2015-09-10
JP6738449B2 (ja) 2020-08-12
CL2016001212A1 (es) 2016-12-09
MX377716B (es) 2025-03-11
CA2931299C (en) 2024-03-05
CN105916881A (zh) 2016-08-31
US10155811B2 (en) 2018-12-18
US10189901B2 (en) 2019-01-29
US9644018B2 (en) 2017-05-09
EA201691027A1 (ru) 2016-12-30
US11642390B2 (en) 2023-05-09
US20170210800A1 (en) 2017-07-27
US10947310B2 (en) 2021-03-16
MA39061A1 (fr) 2017-10-31
US10626173B2 (en) 2020-04-21
US20240091301A1 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
JP6738449B2 (ja) Ａｐｌｎｒモジュレーター及びその使用
JP7759417B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
US10072076B2 (en) Human antibodies to NAv1.7
CN104203980B (zh) 抗‑大‑内皮素‑1(big‑et‑1)抗体及其用途
JP7042816B2 (ja) レプチン受容体をアンタゴナイズする抗原結合性タンパク質
AU2015236073B2 (en) FGF21 receptor agonists and uses thereof
CN110036032A (zh) 抗muc16(粘蛋白16)抗体
JP2025519057A (ja) Ｃｄ３８及び４－１ｂｂに結合する多重特異性抗原結合分子、並びにその使用
CN104781280A (zh) 抗前动力蛋白受体(prokr)抗体及其使用
BR112018007318B1 (pt) Anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
BR122025018407A2 (pt) Anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190213

R150 Certificate of patent or registration of utility model

Ref document number: 6483117

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250